不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
成人急性淋巴细胞白血病的抗体与细胞免疫治疗
英文原题：Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults.
查看英文原题
Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管急性淋巴细胞白血病（ALL）患者的治疗结局已有改善，传统疗法（包括造血干细胞移植）仍常常无法奏效。单克隆抗体、抗体药物偶联物、双特异性T细胞衔接器（BiTE）以及嵌合抗原受体（CAR）T细胞等抗原特异性ALL免疫疗法已显示显著临床疗效，并在快速发展。鉴于这些疗法在复发/难治性ALL患者中疗效确切，目前正努力将其纳入更早期的治疗阶段。本综述介绍用于ALL患者的现有抗体类和细胞类免疫疗法，并提供临床与生物学框架，以指导治疗策略的制定。
展开英文摘要原文
Despite improvements in the outcomes of patients with acute lymphoblastic leukemia (ALL), traditional therapies (including hematopoietic stem cell transplant) often still fail. Antigen-specific immunotherapies for the treatment of ALL such as monoclonal antibodies, antibody-drug conjugates, bispecific T-cell engagers (BiTEs), and chimeric antigen receptor (CAR) T-cells have demonstrated remarkable clinical efficacy and are rapidly evolving.
With indisputable activity in patients with relapsed or refractory ALL, efforts now hope to integrate these agents into earlier phases of treatment. In this review, we will discuss the available antibody and cellular-based immunotherapies for the treatment of patients with ALL and provide a clinical and biologic framework with which to inform treatment approaches.
论文信息
- 作者
- Kimble EL、Cassaday RD
- 单位
- Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.United States
- 文献类型
- 综述
- 期刊
- Leukemia & lymphoma2021 Dec
- 原文标识
- PubMed 34402732 · DOI 10.1080/10428194.2021.1964022